Floatz logo

Dhea

Urinary Incontinence

Hadassah Medical OrganizationPhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Urinary Incontinence cohort.

Asset / SponsorPhaseRating
Xeomin®
Ipsen
Phase 3B
Duloxetine
Institut Mutualiste Montsouris
Phase 3B
SOLIFENACIN
University of California, Irvine
Phase 4CCC
Fesoterodine
Saint Thomas Health
Early Phase 1C
DEXKETOPROFEN
Nurgül KAPLAN
N/AD
METAMIZOLE
Nurgül KAPLAN
N/AD
NEPENTHE
Nurgül KAPLAN
N/AD

Same molecule, other indications

Dhea is also rated in:

postmenopausal atrophic vaginitisDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →
Sexual SatisfactionDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →